Market Exclusive

Chimerix, Inc. (NASDAQ:CMRX) Files An 8-K Submission of Matters to a Vote of Security Holders

Chimerix, Inc. (NASDAQ:CMRX) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07

Submission of Matters to a Vote of Security
Holders.

On June 28, 2017, Chimerix, Inc. (the
Company) held its 2017 Annual Meeting
of Stockholders (the Annual Meeting).
As of May 1, 2017, the record date for the Annual Meeting,
46,651,793 shares of common stock were outstanding and entitled
to vote at the Annual Meeting. At the Annual Meeting, 37,700,899
shares of common stock were present in person or represented by
proxy for the three proposals summarized below.

Proposal 1: Election of directors

The Companys stockholders elected the two persons listed below as
Class I directors, each to serve until the Companys 2020 Annual
Meeting of Stockholders and until their successors are duly
elected and qualified. The final voting results are as follows:

Votes For Votes Withheld Broker Non-Votes
M. Michelle Berrey, M.D., M.P.H. 29,880,415 168,229 7,652,255
Ronald C. Renaud, Jr. 23,642,443 6,406,201 7,652,255

Proposal 2: Ratification of the selection of independent
registered public accounting firm

The Companys stockholders ratified the selection by the Audit
Committee of Ernst Young LLP as the Companys independent
registered public accounting firm for the fiscal year ending
December 31, 2017. The final voting results are as follows:

Votes For 30,366,207
Votes Against 7,318,893
Abstentions 15,799
Broker Non-Votes

Proposal 3: Approval, on a non-binding, advisory basis,
of the compensation of the Companys named executive
officers

The Companys stockholders approved, on a non-binding, advisory
basis, the compensation of the Companys named executive officers.
The final voting results are as follows:

Votes For 29,813,821
Votes Against 204,057
Abstentions 30,766
Broker Non-Votes 7,652,255

About Chimerix, Inc. (NASDAQ:CMRX)
Chimerix, Inc. (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against over five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. CMX157, is its second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir is marketed under the brand name Viread. The Company has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus.

Exit mobile version